Total Payments
$3,358
2024 Payments
$89.76
Companies
17
Transactions
67
Medicare Patients
940
Medicare Billing
$129,292
Payment Breakdown by Category
Consulting$1,935 (57.6%)
Food & Beverage$1,392 (41.4%)
Education$30.97 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,935 | 1 | 57.6% |
| Food and Beverage | $1,392 | 64 | 41.4% |
| Education | $30.97 | 2 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $2,078 | 5 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $318.04 | 15 | $0 (2017) |
| Ipsen Biopharmaceuticals, Inc | $221.31 | 2 | $0 (2019) |
| Amgen Inc. | $178.87 | 10 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $125.14 | 14 | $0 (2017) |
| ARRAY BIOPHARMA INC | $105.92 | 4 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $81.45 | 5 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $77.69 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $35.63 | 2 | $0 (2017) |
| BTG International, Inc. | $24.28 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89.76 | 4 | ARRAY BIOPHARMA INC ($46.63) |
| 2023 | $2,156 | 4 | Eisai Inc. ($2,041) |
| 2022 | $22.06 | 1 | ARRAY BIOPHARMA INC ($22.06) |
| 2019 | $221.31 | 2 | Ipsen Biopharmaceuticals, Inc ($221.31) |
| 2017 | $868.69 | 56 | E.R. Squibb & Sons, L.L.C. ($318.04) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/23/2017 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.84 | General |
| Category: Oncology | ||||||
| 08/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.75 | General |
| Category: Oncology | ||||||
| 08/03/2017 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $7.55 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2017 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Education | In-kind items and services | $22.67 | General |
| Category: Immunology | ||||||
| 07/06/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $8.96 | General |
| Category: HEMATOLOGY | ||||||
| 07/05/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $8.09 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $9.72 | General |
| Category: Oncology | ||||||
| 06/16/2017 | Amgen Inc. | Aranesp (Biological), Nplate, Prolia | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Nephrology | ||||||
| 06/02/2017 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.52 | General |
| Category: Oncology | ||||||
| 05/19/2017 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Oncology | ||||||
| 05/18/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $119.29 | General |
| Category: Oncology | ||||||
| 05/17/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Oncology | ||||||
| 05/17/2017 | Amgen Inc. | — | Education | In-kind items and services | $8.30 | General |
| 05/16/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Anemia | ||||||
| 05/11/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $4.19 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: Oncology | ||||||
| 05/05/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: HEMATOLOGY | ||||||
| 05/03/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Oncology | ||||||
| 04/27/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $1.69 | General |
| Category: Cardiovascular | ||||||
| 04/25/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $0.95 | General |
| Category: Cardiovascular | ||||||
| 04/20/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $6.27 | General |
| Category: Cardiovascular | ||||||
| 04/07/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $8.70 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2017 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.07 | General |
| Category: Oncology | ||||||
| 03/30/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $3.78 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 238 | 359 | $71,427 | $31,436 |
| 2022 | 4 | 230 | 356 | $69,157 | $33,110 |
| 2021 | 4 | 214 | 343 | $61,007 | $31,097 |
| 2020 | 4 | 258 | 450 | $81,300 | $33,648 |
Total Patients
940
Total Services
1,508
Medicare Billing
$129,292
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 99 | $17,575 | $7,658 | 43.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $13,004 | $5,577 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 26 | 40 | $9,580 | $4,503 | 47.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 48 | $8,515 | $3,777 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 52 | 69 | $8,637 | $3,524 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 30 | $7,185 | $3,464 | 48.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,106 | $1,761 | 42.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 23 | $2,825 | $1,173 | 41.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 52 | 77 | $17,457 | $9,028 | 51.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 68 | 100 | $16,898 | $7,748 | 45.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 43 | $9,774 | $5,052 | 51.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 57 | $9,597 | $4,493 | 46.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $9,516 | $4,158 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 39 | 50 | $5,915 | $2,632 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 69 | 121 | $18,723 | $9,508 | 50.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 35 | 53 | $11,465 | $6,200 | 54.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $13,000 | $6,041 | 46.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 45 | $6,960 | $3,644 | 52.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 42 | 63 | $6,314 | $3,319 | 52.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 21 | $4,545 | $2,385 | 52.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 97 | 210 | $32,130 | $13,184 | 41.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 65 | 114 | $24,510 | $10,065 | 41.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 46 | 46 | $14,950 | $6,301 | 42.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 34 | $5,202 | $2,227 | 42.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 34 | 46 | $4,508 | $1,871 | 41.5% |
About Dr. Iman Imanirad, M.D
Dr. Iman Imanirad, M.D is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790872653.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Iman Imanirad, M.D has received a total of $3,358 in payments from pharmaceutical and medical device companies, with $89.76 received in 2024. These payments were reported across 67 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($1,935).
As a Medicare-enrolled provider, Imanirad has provided services to 940 Medicare beneficiaries, totaling 1,508 services with total Medicare billing of $129,292. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Tampa, FL
- Active Since 10/10/2006
- Last Updated 08/10/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1790872653
Products in Payments
- Lenvima (Drug) $1,972
- OPDIVO (Biological) $300.86
- SOMATULINE DEPOT (Drug) $221.31
- BRAFTOVI (Drug) $105.92
- KEYTRUDA (Biological) $81.45
- Stivarga (Drug) $77.69
- JADENU (Drug) $64.32
- Kyprolis (Biological) $50.46
- Nplate (Biological) $42.08
- Neulasta (Biological) $39.48
- Aranesp (Biological) $38.55
- SOLIRIS (Drug) $35.63
- Vistogard (Drug) $24.28
- Perjeta (Biological) $23.92
- VOWST (Biological) $18.85
- ELIQUIS (Drug) $17.18
- KISQALI (Drug) $16.79
- INJECTAFER (Drug) $14.71
- XARELTO (Drug) $14.05
- Xtandi (Drug) $13.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Internal Medicine $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Internal Medicine $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Internal Medicine $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Internal Medicine $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357
Internal Medicine $273,357